BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30452664)

  • 1. Toxicity and clinical outcomes with definitive three-dimensional conformal radiotherapy (3DCRT) and concurrent cisplatin chemotherapy in locally advanced cervical carcinoma.
    Dracham CB; Mahajan R; Rai B; Elangovan A; Bhattacharya T; Ghoshal S
    Jpn J Clin Oncol; 2019 Feb; 49(2):146-152. PubMed ID: 30452664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam.
    Phung HT; Truong MC; Nguyen LT; Dang ATV; Vu TH; Nguyen HT
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):853-859. PubMed ID: 33773550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
    Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
    Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
    Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
    BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study.
    Cihoric N; Tsikkinis A; Vlaskou Badra E; Glatzer M; Novak U; Scherz A; Shelan M; Soldatovic I; Yojena CKK; Aebersold DM; Lössl K
    Radiat Oncol; 2017 Dec; 12(1):202. PubMed ID: 29273076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
    Lakosi F; de Cuypere M; Viet Nguyen P; Jansen N; Warlimont B; Gulyban A; Gennigens C; Seidel L; Delbecque K; Coucke P; Hermesse J; Kridelka F
    Acta Oncol; 2015; 54(9):1558-66. PubMed ID: 26406152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
    Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z
    Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of intensity modulated radiotherapy and three-dimensional conformal radiotherapy with three-dimensional brachytherapy and concurrent chemotherapy for patients with advanced cervical cancer].
    Du XX; Yang H; Zhang HJ; Li LA; Fan WS; Meng YG
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):679-686. PubMed ID: 29060966
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
    Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
    Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent Weekly versus Three Weekly Cisplatin with Radiotherapy in Locally Advanced Uterine Cervical Carcinoma.
    Hasan MR; Bari MA; Alam S; Sah GS
    JNMA J Nepal Med Assoc; 2018; 56(213):842-847. PubMed ID: 31065118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locally advanced cervical cancer: how the improvement in techniques in external beam radiotherapy and brachytherapy impacts on survival outcomes and long-term toxicities.
    Barbera F; Frassine F; Volpi G; Ghedi B; Pasinetti N
    Radiol Med; 2023 Dec; 128(12):1542-1552. PubMed ID: 37640897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.
    Shrivastava S; Mahantshetty U; Engineer R; Chopra S; Hawaldar R; Hande V; Kerkar RA; Maheshwari A; Shylasree TS; Ghosh J; Bajpai J; Gurram L; Gulia S; Gupta S;
    JAMA Oncol; 2018 Apr; 4(4):506-513. PubMed ID: 29423520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
    Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
    Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of concomitant chemoradiotherapy incorporating high-dose-rate brachytherapy to treat locally advanced cervical cancer.
    Lee HJ; Kim YS; Shin SS; Nam JH; Kim YT; Han S; Choi EK
    Tumori; 2012; 98(5):615-21. PubMed ID: 23235757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
    Schefter TE; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Gaffney DK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1179-84. PubMed ID: 22342094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute toxicity of postoperative intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for cervical cancer: The role of concomitant chemotherapy.
    Marjanovic D; Plesinac Karapandzic V; Stojanovic Rundic S; Tomasevic A; Saric M; Miskovic I; Nidzovic B; Petrasinovic P
    J BUON; 2019; 24(6):2347-2354. PubMed ID: 31983105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.